Matt Carter

Matt Carter advises private equity sponsors, institutional direct investors, and strategic acquirers on a wide range of US and cross-border transactions, including leveraged buyouts, growth equity investments, joint ventures, and restructurings. He counsels clients across an array of verticals, including: healthcare and life sciences; sports, media & entertainment; technology; infrastructure; and consumer products.

Matt regularly counsels sponsors across the full investment lifecycle, from platform acquisitions and add-ons through growth equity investments and exits. His cross-border experience includes advising publicly traded strategic acquirers, private equity sponsors, multinational infrastructure investors, pension funds, and financial services firms on transactions spanning the globe.

Beyond his institutional practice, Matt advises family offices – including those of high-profile athletes and entertainers – on joint ventures, endorsement deals, and other corporate and commercial matters.

• Represented US private equity sponsors in numerous platform acquisitions in the medical physics, specialty dental, dental laboratory, contract healthcare manufacturing, and clinical trial support spaces, together with a large number of related add-on transactions
• Represented the family office of a multiple-time MVP NBA player in several joint ventures, endorsement deals, and corporate matters
• Represented a post-acute care provider group in connection with several financings, corporate, commercial and regulatory matters
• Represented a US private equity sponsor in its strategic partnership with, and equity investment in, a leading US manufacturer of orthotic and prosthetic products and in subsequent joint venture and add-on acquisition matters, through to the successful divestment of the platform
• Represented publicly traded Japanese client KAKEN Pharmaceutical Co., Ltd. in its acquisition of Aadi Bioscience, Inc. and substantially all of its assets, including FYARRO^®, a drug for treating malignant perivascular epithelioid cell tumor (PEComa) in adults
• Represented a US search engine optimization company in its sale, for cash and stock, of substantially all assets to a Nasdaq Nordic-listed online gaming concern
• Represented a US private equity sponsor in its sale of a majority stake in a home décor e-commerce retailer
• Represented a US private equity sponsor in its exit of a home flooring products platform
• Represented a leading educational technology company in its cross-border purchase of substantially all assets of an online learning platform, with a related equity financing round
• Represented a leading US private equity sponsor in its exit of a home healthcare business
• Represented a US debt fund in connection with the take-private acquisition of an NYSE-listed sleep products company
• Represented a private equity sponsor in its sale of a biotherapeutics-focused portfolio company to a London-listed acquirer*
• Represented a major Canadian pension fund in several growth equity direct investments focused on the technology and life sciences spaces*
• Represented a European financial services firm in its acquisition of a US-based provider of ETF data and analytics*
• Represented a multinational infrastructure investor’s US subsidiary in separate acquisitions of substantially all assets of almost a dozen private aviation and engineering companies*
• Represented a NASDAQ-listed technical and consulting company in its acquisition of all outstanding shares of a nationwide provider of energy efficiency programs*
• Represented a private equity sponsor in a PIPE in a NASDAQ-listed freight and logistics company*
• Represented a private equity sponsor in a growth equity financing of a food products concern*
• Represented a high-tech materials company in its sale of substantially all its assets to the portfolio company of a French multinational*
• Represented a private equity sponsor in its acquisition of a specialized food distributor*
• Represented an iconic American manufacturer in its suite of eight Section 363 carve-out asset sales following a contested Chapter 11 auction*
• Represented a major national mortgage lender in various restructuring and divestment matters*
• Represented a sports media sponsor in its fund formation and platform acquisition*
• Represented the founders of an international medical device company in their management buyout*
• Represented a NASDAQ-listed pharmaceuticals company in a wide variety of corporate governance and US Securities and Exchange Commission disclosure matters*
• Represented a private equity sponsor in its co-investment in a Vietnamese furniture manufacturing concern*
• Represented the portfolio company of a multinational infrastructure investor in its sale of interests in certain regulated electric transmission and telecommunications businesses*
• Represented a major Japanese keiretsu in certain cross-border mergers and acquisitions*
• Represented a sports media company in its sale of substantially all assets to a strategic acquirer*
• Represented a Brooklyn-based microenterprise project in certain pro bono corporate governance and commercial matters*
• Represented the US partners of a premier European soccer team in their youth soccer joint venture*
• Represented a century-old New York nonprofit clinic provider in its merger with a regional medical hospital*

*Matter handled prior to joining McDermott.